Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against DermTech, Inc. (“DermTech” or the “Company”) (NASDAQ: DMTK) on behalf of DermTech stockholders. Our investigation concerns whether DermTech has violated the federal securities laws and/or engaged in other unlawful business practices.

Click here to participate in the action.

The investigation by a law firm concerns whether certain DermTech directors breached their fiduciary duties and caused damage to the company and its shareholders.

San Diego, CA based DermTech, a molecular diagnostic company, develops and markets novel non-invasive genomics tests to aid in the diagnosis and management of various skin conditions, including skin cancer and inflammatory diseases in the United States. DermTech, Inc. reported that its annual Total Revenue rose from $11.83 million in 2021 to $14.51 million in 2022, and that its Net Loss increased from $78.33 million in 2021 to $116.68 million in 2022.

Shares of DermTech declined from over $84 per share in February 2021 to as low as $1.55 per share in late December 2022.

If you purchased or otherwise acquired DermTech shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231006056660/en/